◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral SKIP-FOR-NOW HIGH

Mirtazapine

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict SKIP-FOR-NOW HIGH

Mirtazapine's primary clinical effects (sedation, appetite stimulation, +2-10 lb weight gain in 3-6 months) are direct inversions of Dylan's MMA performance + body-composition + cognitive-output goals. Verdict would only flip to OPTIONAL-ADD if Dylan develops clinical depression with comorbid insomnia + appetite loss, in which case mirtazapine becomes a tier-1 Rx specifically because of the same effects that disqualify it now. No nootropic case; no chronotype-migration case; no off-label use that survives the cost-benefit for an athlete.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    SKIP-FOR-NOW

    / HIGH confidence. Sedation directly impairs the 6-12 hr cognitive output that's Dylan's economic + biological priority. Morning grogginess + "Remeron hangover" eats into the highest-value cognitive hours. Weight gain + appetite stimulation invert MMA performance + body-composition goals (weight class, strength-to-weight, conditioning). Restless legs syndrome (8-28% incidence) is a direct disqualifier for an athlete whose legs do daily work. No off-label use case survives the cost-benefit for this profile. Verdict only flips if clinical depression with comorbid insomnia + weight loss develops, in which case the same effects become therapeutic features.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    with caveats for the specific phenotype of "depression + insomnia + appetite loss." High-efficacy antidepressant for the right presentation. Acceptability concerns (weight gain, sedation) are real — many users discontinue. Probably not first-line; reserve for SSRI-non-responders or patients who specifically need the sleep + appetite features.

  • 50+, mild cognitive decline
    OPTIONAL-ADD

    for late-life depression with appetite loss + insomnia (a common geriatric presentation). Watch agranulocytosis risk (more cases reported in older adults), fall risk from sedation + orthostatic hypotension, polypharmacy interactions. Sometimes preferred specifically because the appetite stimulation is a feature in declining-weight elderly.

  • Anxiety-prone
    NEUTRAL

    Effective for anxious depression but not first-line for primary anxiety; theanine + magnesium + behavioral tools usually preferred. Mirtazapine's anxiolytic action is real but bundled with the sedation + weight-gain package.

  • High athletic load, tested status
    SKIP

    Same as Dylan profile — sedation + weight gain + RLS are direct disqualifiers regardless of WADA status (mirtazapine is NOT WADA-banned, but the performance-undermining effects make WADA status irrelevant).

  • Sleep-disordered (primary insomnia, no depression)
    OPTIONAL-PRN

    at low dose. A-tier evidence from DREAMING + MIRAGE trials for off-label insomnia. But for an athlete or high-cognitive-output user, daridorexant or agomelatine offer cleaner profiles without weight gain. Mirtazapine 7.5 mg is a reasonable cheap last-line option for people who have failed cleaner alternatives or for whom cost is prohibitive.

  • Sleep-disordered (depression + insomnia + appetite loss)
    PRIMARY-PICK

    or STRONG-CANDIDATE. This is the population where mirtazapine genuinely shines — three bird, one stone. Better than SSRI + Z-drug combo for this specific phenotype.

  • Recovery-focused (post-injury, post-illness, cachexia)
    OPTIONAL-ADD

    if appetite + weight + sleep are the bottleneck. Same effects that disqualify athletes are therapeutic in cachexia/recovery. Not Dylan-relevant.

  • Strength/anabolic-focused
    SKIP

    unless cachexic. Weight gain is poorly distributed (more fat than muscle), reduced spontaneous activity, no anabolic axis benefit.

  • Tested in WADA-sanctioned competition
    N

    WADA-banned. But practically incompatible with athletic performance regardless.

▸ Subjective experience (deep)

Per clinical trial reports + extensive forum data:

Onset:

  • Sedation: 30-60 minutes after dose. Comes on as heavy, antihistamine-style drowsiness — not the GABAergic mush of benzos/Z-drugs, not the orexin-permissive feel of DORAs. More like "you took 75 mg of Benadryl with antidepressant attached."
  • Appetite stimulation: same evening or next day. Many users describe waking up ravenous; some experience compulsive nighttime eating ("Remeron munchies").
  • Antidepressant effect: 1-2 weeks (notably faster than SSRIs in some cohorts, particularly on sleep + appetite symptoms).
  • Anxiolytic effect: 1-3 weeks.

Peak / steady-state experience (typical responder, 15-30 mg evening dose):

  • Heavy sedation 8-12 hours post-dose. Sleep onset latency dramatically reduced; sleep depth subjectively "deeper" but morning grogginess + "Remeron hangover" common.
  • Carbohydrate cravings + increased meal sizes — described as compelled, not chosen. Particularly for sweets + bread + cereal.
  • Weight gain trajectory — most patients gain 2-10 lb in first 3-6 months; ~20-40% gain ≥7 lb. Sometimes described as "fastest weight gain of any antidepressant" in head-to-head clinical experience.
  • Mood lift — described as "sturdy" rather than "bright" — fewer lows, less rumination, more emotional padding. Less of the "wheee" feel of bupropion or stimulants.
  • Reduced anxiety + faster sleep onset + fewer middle-of-night awakenings — the sleep + anxiety lift is actually one of the strongest selling points for the right patient.
  • Dry mouth in ~25% of users — antimuscarinic-flavored despite no direct anticholinergic action.
  • Vivid dreams — common, especially first weeks; some users find these pleasant, others disruptive.

The "Remeron hangover":

  • Morning grogginess persistent for some users — described as sluggish, slow-thinking, "not myself" feeling 2-4 hours after wake.
  • Mayo Clinic Connect and patient forums have lengthy threads on this — for many users it never fully clears.
  • Particularly bad at 7.5-15 mg (where H1 dominates) and may improve at 30-45 mg (where α2 antagonism begins counteracting H1).
  • For Dylan's 6-12 hour cognitive workload, even a 1-2 hour morning fog window is disqualifying.

The athlete-specific subjective:

  • Patient reports of "couldn't finish my usual 5K" after dose increase
  • Reduced spontaneous physical activity (well-documented)
  • Combined with appetite stimulation → body composition trajectory is reliably negative for performance athletes
  • One published case (Kethini 2004, J Pharm Pract Res) directly documents mirtazapine-associated rapid weight gain + decreased physical activity
▸ Tolerance + cycling deep dive
  • Tolerance buildup: PARTIAL and ASYMMETRIC.
    • Sedation tolerance: develops over weeks for many (not all) users. Initial heavy sedation often fades to manageable drowsiness by week 2-4 (Tachyphylaxis to Sedative Action of Mirtazapine, AmJCaseRep 908412 / PMC5907691).
    • Appetite + weight gain tolerance: does NOT develop. Weight trajectory continues in many users.
    • Antidepressant tolerance (poop-out): common to most antidepressants, not mirtazapine-specific.
  • Recommended cycle: None. Designed for steady-state daily use.
  • Reset protocol: Not applicable. If poop-out → switch class.
  • Discontinuation: Generally smoother than SSRIs but discontinuation symptoms reported (dizziness, nausea, anxiety, insomnia rebound). Tapering recommended over 2-4 weeks for chronic users; faster taper feasible for short-duration low-dose use.
▸ Stacking deep dive

Synergistic with

  • L-tryptophan (substrate) — feeds the upstream serotonin pool that mirtazapine then disinhibits + funnels through 5-HT1A. Theoretically synergistic for mood + sleep. Not formally needed for clinical efficacy.
  • CBT for insomnia / depression — behavioral component matters; mirtazapine alone often used as bridge to CBT response.
  • California Rocket Fuel (mirtazapine + venlafaxine) — Stahl-coined combination. Mirtazapine α2 + 5-HT2/3 antagonism complements venlafaxine's SNRI mechanism + cancels venlafaxine's GI/sexual side effects via 5-HT2A/3 blockade. Used for treatment-resistant depression. Robust mechanistic logic.

Avoid stacking with

  • MAOIs (phenelzine, tranylcypromine, isocarboxazid, selegiline at high doses) — serotonin syndrome risk. Selegiline 1-2.5 mg/day (in Dylan's V5+ plan) is MAO-B selective so theoretical risk is low, but combination not formally studied; avoid stacking.
  • Other strong serotonergic agents (SSRIs at full doses, SNRIs, tramadol, MDMA, dextromethorphan, tianeptine at high doses) — additive serotonergic risk
  • Other CNS depressants (alcohol, benzos, Z-drugs, opioids, gabapentinoids, phenibut, GHB, DORAs like daridorexant) — additive sedation + respiratory depression at high combined load
  • Strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin, St. John's wort) — reduce mirtazapine exposure, may lose efficacy
  • Strong CYP1A2/2D6/3A4 inhibitors (fluvoxamine, ketoconazole, ciprofloxacin) — increase mirtazapine exposure, intensify side effects
  • Bromantane (in V5 plan) — same-evening combination contradictory: bromantane upregulates DA synthesis (wake/motivation), mirtazapine sedates. AM bromantane + PM mirtazapine theoretically possible but mirtazapine is contraindicated for Dylan anyway
  • Modafinil — same-day combination has been used (modafinil AM, mirtazapine PM) as "California Rocket Fuel for sleep + wake" but this is not a Dylan-relevant pattern given the verdict

Neutral / safe co-administration

  • All V4 stack components (DHA, magtein, citicoline, NAC, PS, magnesium glycinate, curcumin phytosome, rhodiola, theanine, D3+K2, beta-alanine, vitamin C) — no significant PK or PD interactions
  • Caffeine — CYP1A2 substrate, mild interaction direction is opposing (caffeine doesn't meaningfully induce CYP1A2 at consumed doses); no clinical concern
  • Creatine — no interaction
▸ Drug interactions deep dive

CYP enzymes involved in mirtazapine metabolism:

  • CYP2D6 (primary at low concentrations, ~65% of hydroxylation at 2 µM)
  • CYP1A2 (significant contribution, 30-50% of hydroxylation; higher at higher concentrations)
  • CYP3A4 (>50% of N-demethylation pathway)

Mirtazapine itself is NOT a clinically significant CYP inducer or inhibitor — interactions go one direction (other drugs affect mirtazapine; mirtazapine doesn't significantly affect other drugs).

Interactor Effect Action
MAOIs (any type within 14 days) Serotonin syndrome CONTRAINDICATED
Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) ↑ mirtazapine exposure Caution; lower dose
Strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) ↑ mirtazapine exposure Caution; lower dose
Strong CYP2D6 inhibitors (paroxetine, fluoxetine, bupropion, quinidine) ↑ mirtazapine exposure Caution
Strong CYP3A4 inducers (carbamazepine, phenytoin, rifampin, St. John's wort) ↓ mirtazapine exposure May lose efficacy
Alcohol Additive sedation + impairment Avoid combination
Benzos / Z-drugs / opioids / DORAs / gabapentinoids Additive CNS depression Avoid or use with caution
Tramadol Serotonergic + RLS-potentiation risk Avoid
Warfarin Modest INR increase reported Monitor INR
QT-prolonging drugs Modest additive QT risk Use caution

Hormonal contraceptives: No significant interaction; mirtazapine doesn't induce CYP3A4.

▸ Pharmacogenomics
  • CYP2D6: Primary axis. Poor metabolizers (PMs) — ~7-10% of Caucasians — have substantially elevated mirtazapine exposure and prolonged half-life. Side effect intensity (sedation, weight gain, dry mouth) likely worse in PMs. Ultra-rapid metabolizers (UMs) — ~1-3% — may have subtherapeutic exposure and functional non-response.
  • CYP1A2 polymorphisms (1F, 1C — same as for agomelatine): Affect mirtazapine PK secondarily. Smokers + *1F/*1F homozygotes have higher CYP1A2 activity → may underdose.
  • CYP3A4*22: Reduced-activity variant → modest exposure increase. Same allele relevant to daridorexant.
  • 23andMe coverage (Dylan's June 2026 results): rs762551 (CYP1A2*1F) reliable. CYP2D6 PM/UM status requires interpretation of multiple SNPs (*4, *5, *6, *10, *17, *41 deletion/duplication patterns) — Promethease + raw data parsing or specialty PGx panel needed for full picture.
  • No formal CPIC dosing guideline for mirtazapine + CYP2D6 as of 2026, but mirtazapine is on the watchlist of drugs where PGx-informed dosing is plausible.
  • Nordic/British ancestry: typical Caucasian PM/UM distribution; ~7-10% PM probability for Dylan pre-genotyping.
▸ Sourcing deep dive

Globally available, generic since ~2004, cheap. Easiest sourcing of any compound on Dylan's research list.

Path Vendor Cost Reliability Notes
US Rx (insurance) Any pharmacy $0-15/mo copay HIGH Generic on virtually all formularies including Medicare/Medicaid
US Rx (cash, GoodRx) Any pharmacy ~$4.50-10/mo for 30 ct 15 mg HIGH One of the cheapest psychiatric Rx anywhere
US Rx (cash, retail) Any pharmacy $30-65/mo (15 mg, 30 ct) HIGH Even retail cash is cheap
US Rx (telehealth) Klarity, Done, Cerebral, Quick.MD, primary care telehealth Visit fee + Rx cost HIGH Easily prescribed via telehealth — not controlled
Indian pharmacy Standard Indian generic mfgrs $5-15/mo HIGH Available at modafinil-tier vendors but no need given US generic price
Brand Remeron (US) Schering / Organon $241-250/mo HIGH Brand premium massive; no clinical reason to use brand

Practical sourcing for Dylan if it ever became indicated: Telehealth psychiatrist or PCP → generic mirtazapine 7.5-15 mg → GoodRx coupon ($4.50-10/mo). No sourcing friction at all. The barrier is the verdict, not the supply chain.

▸ Biomarkers to track (deep)

Baseline (before starting — only relevant if it ever became indicated)

  • CBC with differential, ANC — required baseline given agranulocytosis risk
  • CMP, LFTs, fasting lipid panel — given metabolic effects + rare hepatotoxicity
  • Body weight, BMI, waist circumference
  • HAM-D / PHQ-9 if depression
  • ISI / PSQI if insomnia
  • Sleep diary 14 days pre-start
  • CYP2D6 + CYP1A2 + CYP3A4 genotype (23andMe / specialty PGx)

During use

  • CBC with differential at 2, 4, 8, 12 weeks then quarterly first year — look for ANC drift
  • Body weight + waist weekly first month, then monthly — early detection of weight trajectory
  • Fasting lipids at baseline + 12 + 24 weeks — independent of weight gain effect
  • PHQ-9 / ISI every 2-4 weeks first 12 weeks
  • Morning alertness VAS daily — tracks "Remeron hangover" persistence
  • RLS check — ask weekly first 4 weeks
  • For athlete (hypothetical): weight-class margin, training capacity, sparring intensity tolerance, recovery quality

Post-discontinuation

  • Sleep diary for 4-8 weeks — assess insomnia rebound
  • Weight trajectory — appetite normalizes; weight may slowly normalize over 6-12 months but often partially persists
  • Mood tracking — if used for MDD, monitor for relapse
▸ Controversies / open debates Live debate

  1. The efficacy-acceptability paradox. Cipriani 2018 ranks mirtazapine in the top efficacy tier but middling acceptability tier — the highest-efficacy/highest-tolerability drugs were escitalopram, vortioxetine, and agomelatine. The clinical question: is mirtazapine's superior raw efficacy worth the dropout from side effects? Answer is patient-specific, but for athletes / brain-priority users, the side effect profile usually wins the trade-off and sends them to better-tolerated alternatives.

  2. The low-dose paradox interpretation. Some prescribers interpret "lower doses are more sedating" as a reason to titrate UP to reduce sedation (counterintuitive but mechanistically supported). Others interpret it as a reason to use LOW doses for off-label sleep indication (where sedation is the goal). Both interpretations are mechanistically valid; depends on the indication. For Dylan, both directions are wrong — sedation isn't the goal, neither is depression Rx, so the dose discussion is moot.

  3. Off-label insomnia ethics. A 2025 medRxiv preprint flagged the rising off-label use of low-dose mirtazapine as a "public health concern" — concern is that the antidepressant is being routinely prescribed for insomnia in primary care without the long-term safety monitoring (CBC, lipids, weight) that the antidepressant indication traditionally triggers. For Dylan, irrelevant given the verdict, but worth noting that "low-dose mirtazapine for sleep" is increasingly common and not without concerns.

  4. Tachyphylaxis to sedation — does it really happen? Mixed evidence. Some users do see sedation fade by week 2-4; others have persistent grogginess that never clears. Pre-treatment predictors are unclear. Pharmacogenomic CYP2D6 status may explain some of the variability.

  5. Weight gain mechanism — H1 vs 5-HT2C vs metabolic. Multiple mechanisms contribute; the "weight gain is just from sedation reducing activity" theory is incomplete (Heinz 2023 Naunyn-Schmiedeberg shows weight-gain-INDEPENDENT lipid effects). Real mechanism is multi-receptor + direct metabolic substrate partitioning shift.

  6. RLS incidence range (8-28%) — why so wide? Methodology differences across studies; concomitant medications (tramadol, dopamine blockers) potentiate; pre-existing RLS often unrecognized at baseline. Real incidence probably ~10-15% in clean populations.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: SKIP-FOR-NOW / HIGH confidence. Sedation + weight gain + appetite stimulation + restless legs syndrome are direct inversions of Dylan's MMA + cognitive output + body composition + late-chronotype-migration goals. No nootropic case; no off-label case that survives the cost-benefit. Verdict would only flip to OPTIONAL-ADD if clinical depression with comorbid insomnia + weight loss develops, where the same effects become therapeutic features. Encyclopedia entry already correctly placed mirtazapine on the "sedating antidepressants, not nootropic" skip list — this file confirms and elaborates with high confidence.
▸ Open questions / gaps Open
  1. Will Dylan's late-chronotype migration produce any sleep-onset complaint that escalates to needing an Rx sleep aid? If yes, daridorexant (orexin antagonist, no weight gain) or agomelatine (melatonergic, no weight gain) are the right tools — NOT mirtazapine.
  2. CYP2D6 status from 23andMe (June 2026): Determines theoretical mirtazapine exposure if ever needed. PM status would intensify everything (sedation, weight gain, sides) — pushes verdict harder toward SKIP. UM status would mean lower exposure but doesn't change the goal mismatch.
  3. Bloodwork baseline (June 2026): Lipid panel + CBC baseline relevant if mirtazapine ever pursued. Currently irrelevant given verdict.
  4. Does "California Rocket Fuel" (venlafaxine + mirtazapine) for treatment-resistant depression have any long-term follow-up data? Stahl-coined combination; widely used clinically but not deeply studied long-term. Not relevant for Dylan now, but worth tracking if depression presentation ever required it.
▸ Sources (full, with our context)
Back to compact view